Division of Cardiovascular Intensive Care, Nippon Medical School Hospital.
Department of Cardiovascular Medicine, Nippon Medical School.
J Nippon Med Sch. 2021 Nov 17;88(5):432-440. doi: 10.1272/jnms.JNMS.2021_88-601. Epub 2021 Mar 9.
Because development of acute coronary syndrome (ACS) worsens the prognosis of patients with coronary artery disease, preventing recurrent ACS is crucial. However, the degree to which secondary prevention treatment goals are achieved in patients with recurrent ACS is unknown.
214 consecutive ACS patients were classified as having First ACS (n=182) or Recurrent ACS (n=32), and the clinical characteristics of these groups were compared. Fifteen patients died or developed cardiovascular (CV) events during hospitalization, and the remaining 199 patients were followed from the date of hospital discharge to evaluate subsequent CV events.
Patients in the Recurrent ACS group were older than those in the First ACS group (76.8±10.8 years vs 68.8±13.4 years, p=0.002) and had a higher rate of diabetes mellitus (DM) (65.6% vs 36.8%, p=0.003). The rate of achieving a low-density lipoprotein cholesterol (LDL-C) level of <70 mg/dL in the Recurrent ACS group was only 28.1%, even though 68.8% of these patients were taking statins. An HbA1c level of <7.0% was achieved in 66.7% of patients with recurrent ACS who had been diagnosed with DM. Overall, 12.5% of patients with recurrent ACS had received optimal treatment for secondary prevention. CV events after hospital discharge were noted in 37.9% of the Recurrent ACS group and 21.2% of the First ACS group (log-rank test: p=0.004). However, recurrent ACS was not an independent risk factor for CV events (adjusted hazard ratio: 2.09, 95% confidence interval: 0.95 to 4.63, p=0.068).
Optimal treatment for secondary prevention was not achieved in some patients with recurrent ACS, and achievement of the guideline-recommended LDL-C goal for secondary prevention was especially low in this population.
急性冠状动脉综合征(ACS)的发展使冠心病患者的预后恶化,因此预防 ACS 复发至关重要。然而,尚不清楚 ACS 复发患者二级预防治疗目标的达标程度。
将 214 例连续 ACS 患者分为首次 ACS(n=182)和复发 ACS(n=32),比较两组患者的临床特征。15 例患者住院期间死亡或发生心血管(CV)事件,其余 199 例患者从出院日起随访,以评估后续 CV 事件。
复发 ACS 组患者年龄大于首次 ACS 组(76.8±10.8 岁 vs 68.8±13.4 岁,p=0.002),糖尿病(DM)发生率更高(65.6% vs 36.8%,p=0.003)。尽管 68.8%的患者服用他汀类药物,但复发 ACS 组 LDL-C 水平<70mg/dL 的达标率仅为 28.1%。复发 ACS 且被诊断为 DM 的患者中,有 66.7%的患者 HbA1c 水平<7.0%。总体而言,有 12.5%的复发 ACS 患者接受了二级预防的最佳治疗。复发 ACS 组中有 37.9%的患者在出院后发生 CV 事件,首次 ACS 组中有 21.2%的患者发生 CV 事件(log-rank 检验:p=0.004)。然而,复发 ACS 并不是 CV 事件的独立危险因素(调整后危险比:2.09,95%置信区间:0.95 至 4.63,p=0.068)。
部分复发 ACS 患者未接受二级预防的最佳治疗,且该人群二级预防推荐 LDL-C 目标的达标率尤其低。